Acquisition

The Center acquires dormant skincare brand Boscia for a 2027 relaunch

What's the deal? Beauty accelerator The Center and dermatologist Mamina Turegano have acquired skincare brand Boscia from Japanese cosmetics company FANCLDealroom has a profile for this one. Try Dealroom →. Terms were not disclosed. The buyers plan a direct-to-consumer relaunch in the first quarter of 2027.

What each side brings: The Center, founded by Ben Bennett, is a beauty accelerator whose portfolio includes Phlur, SaltairDealroom has a profile for this one. Try Dealroom →, and NaturiumDealroom has a profile for this one. Try Dealroom →. Turegano is a triple board-certified dermatologist based in New Orleans with over 16 years of experience.

Why now? FANCL launched Boscia in California in 2002, but the brand reportedly closed in 2024. The Center aims to revive it by pairing its Japanese skincare heritage with modern dermatology.

What's the endgame? The buyers plan to preserve Boscia's Japanese philosophy, ingredients, and rituals while updating its approach to formulation, efficacy, and safety. For Turegano, the appeal is personal.

"Boscia has always felt personal to me because of its Japanese roots and its appreciation for the rituals of caring for your skin," she said. Bennett said the brand's "history, its Japanese skincare philosophy and the excitement people felt around its products" drove the deal.

What could go wrong? This is a brand-revival bet, not a large strategic buy. Its success hinges on whether the relaunch can rebuild consumer interest before Boscia secures retail distribution.

The signal: The sale reflects an active beauty deal market, where buyers favour skincare brands with clear identity and clinical credibility — recent examples include GaldermaDealroom has a profile for this one. Try Dealroom →'s $1.5 billion deal for ZO Skin HealthDealroom has a profile for this one. Try Dealroom → and BridgepointDealroom has a profile for this one. Try Dealroom →'s purchase of Obagi Medical. Boscia represents a smaller, lower-risk play: reanimating a dormant name rather than buying a scaled business.

Read more: prnewswire.com

Image credit: Phillip Pessar

More top stories